Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer

Inclusion Criteria:

Male with original diagnosis of adenocarcinoma of the prostate with prior definitive therapy

Suspicion of recurrence or persistence

after radiotherapy or cryotherapy: 3 consecutive PSA rises and/or PSA rise by 2.0 ng/mL or more above nadir (ASTRO-Phoenix)
after prostatectomy, PSA > 0.2 ng/mL on 2 or more determinations (recurrence), or failure of PSA to fall to undetectable levels post-prostatectomy (persistence) (American Urological Association)
For patients who previously had radical prostatectomy, salvage radiotherapy is one likely treatment plan; for patients who initially underwent radiotherapy (including brachytherapy), confirmation of low volume disease is needed to define (local) treatment.
Life expectancy of 6 months or more as judged by the investigator
Willing and able to undergo all study procedures
Informed consent in writing

Exclusion Criteria:

Age: less than18 years
Contraindications to any of the ingredients of [18F]PSMA-1007
Close affiliation with the investigational site
At the time of enrolment into this study, participating in another therapeutic clinical trial or has completed study participation in another therapeutic clinical trial within 5 days of enrolment into this trial
Having been previously enrolled in this clinical trial
Mental conditions rendering the subject incapable to understand the nature, scope, and consequences of the trial
Being clinically unstable or requiring emergency treatment
Patients who are unwilling to consider a biopsy if clinically recommended
Patients who are unable to undergo a PET/CT scan
Patients for whom systemic therapy is the most likely course regardless of PET findings.